Overview
CVM market data
Price History
CVM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$21.72 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.69 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -5,445.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.89 – $13.48 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $25.5M · P/B 4.61 · P/S 45.64.
Company News
CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral OncologyBenzinga · Aug 4, 2026, 12:06 PM
CEL-SCI Announces Multikine Phase 3 Data Accepted For Publication In Oral Oncology, Citing 73% Five-Year Survival vs. 45% For Standard Of Care In Low PD-L1 Head And Neck CancerBenzinga · Jul 30, 2026, 12:37 PM
CEL-SCI shares are trading lower. The company announced the launch of its global Confirmatory Registration Study of Multikine as a neoadjuvant treatment for locally advanced primary head and neck cancer.Benzinga · Jul 13, 2026, 5:35 PM
CEL-SCI To Launch Phase 3 Confirmatory StudyBenzinga · Jul 13, 2026, 12:07 PM
CEL-SCI And Saudi Amarox Sign Agreement To Commercialize Multikine In Saudi ArabiaBenzinga · Jun 24, 2026, 12:10 PM
8-K filing — CEL SCI CORP (CVM)SEC EDGAR · Jun 16, 2026, 9:03 PM
CEL-SCI Announces Dual-Track Strategy To Bring Multikine To Patients With Head And Neck Cancer Through Parallel Regulatory Pathways In The U.S. And Saudi ArabiaBenzinga · Jun 16, 2026, 12:15 PM
CEL‑SCI To Sign Saudi Amarox Deal At BIO International Convention 2026, Advancing Multikine Commercialization In Saudi ArabiaBenzinga · Jun 12, 2026, 12:05 PM
CEL-SCI Q2 EPS $(0.67) Down From $(0.08) YoYBenzinga · May 15, 2026, 10:56 PM
CEL SCI shares are trading higher after a Form 4 filing showed its CEO purchased 100,000 shares at an average price of $1.19 each.Benzinga · May 14, 2026, 7:45 PM